PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07292-1 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Caroline Burgard und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Prostate-Specific Antigen, Oligopeptides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universität des Saarlandes.
Abstract (Originalsprache)
Background
Prostate-specific membrane antigen (PSMA)-directed positron emission tomography/computed tomography (PET/CT) has emerged as a highly accurate imaging modality for detecting tumor lesions in patients with biochemical recurrence (BCR) of prostate cancer (PC). While detection rates of lesions suspicious for PC relapse are known to increase with rising prostate-specific antigen (PSA) levels, data on the efficacy of PSMA PET/CT at very low PSA values (≤ 0.2 ng/mL) remain limited.
Methods
In this multicenter study, we analyzed 321 patients with BCR and a PSA value ≤ 0.2 ng/mL across five German academic centers, using three different PSMA-targeted radiotracers: [ 68 Ga]Ga-PSMA-11, [ 68 Ga]Ga-PSMA I&T, and [ 18 F]PSMA-1007 and analyzed the detection rates and potential predictive parameters.
Results
The overall pooled detection rate was 29.6%. No statistically significant differences in detection rates were observed between the three radiotracers ([ 68 Ga]Ga-PSMA-11 29.4% vs. [ 68 Ga]Ga-PSMA I&T, 22.5% vs. [ 18 F]PSMA-1007 32.4%, p ≥ 0.314). Detection rates were significantly higher in patients with a PSA level > 0.15 ng/mL ( p = 0.029, φ = 0.122), in those with an initial Gleason score > 7 ( p = 0.018, φ = 0.141) and in those receiving androgen deprivation therapy ( p = 0.031, φ = 0.120).
Conclusion
All three radiotracers demonstrated comparable diagnostic performance, with no significant superiority observed between the 68 Ga- and 18 F-labeled tracers in the patient sample investigated (overall pooled detection rate: 29.6%). This positivity rate can serve as an expectation horizon for both the attending physician and the patient in the case of low PSA values. Further studies with larger cohorts, preferably conducted in a prospective setting, are needed to confirm and expand upon our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Saarland University- Medical Center, Kirrberger Str. 100, Geb. 50, D-66421, Homburg, Germany.
- Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
- Department of Nuclear Medicine, Johannes Gutenberg University- Medical Center, Mainz, Germany.
- Department of Nuclear Medicine, Ludwig Maximilian University of Munich- University Hospital, Munich, Germany.
- Bavarian Cancer Research Center (BZKF), Partner Site Munich, Munich, Germany.
- Charité- Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
ORCID-Profile: Florian Rosar
Förderung
- Universität des Saarlandes
Zitieren
APA
Burgard, C., Frei, M., Blickle, A., Hartrampf, P. E., Hoffmann, M. A., Schreckenberger, M., Schmid, H. P., Unterrainer, L., Rogasch, J., Galler, M., Ezziddin, S., & Rosar, F. (2025). PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07292-1
Vancouver
Burgard C, Frei M, Blickle A, Hartrampf PE, Hoffmann MA, Schreckenberger M, et al. PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07292-1
BibTeX
@article{Burgard2025,
author = {Burgard, Caroline and Frei, Madita and Blickle, Arne and Hartrampf, Philipp E and Hoffmann, Manuela A and Schreckenberger, Mathias and Schmid, Hans-Peter and Unterrainer, Lena and Rogasch, Julian and Galler, Markus and Ezziddin, Samer and Rosar, Florian},
title = {PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07292-1}
}
EUVIMED